Searching for new biomarkers in ovarian cancer patients:Rationale and design of a retrospective study under the Mermaid III project by Hentze, Julie L. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Searching for new biomarkers in ovarian cancer patients
Hentze, Julie L.; Høgdall, Claus; Kjær, Susanne K.; Blaakær, Jan; Høgdall, Estrid
Published in:
Contemporary Clinical Trials Communications
DOI:
10.1016/j.conctc.2017.10.003
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Hentze, J. L., Høgdall, C., Kjær, S. K., Blaakær, J., & Høgdall, E. (2017). Searching for new biomarkers in
ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project.
Contemporary Clinical Trials Communications, 8, 167-174. https://doi.org/10.1016/j.conctc.2017.10.003
Download date: 03. Feb. 2020
Contents lists available at ScienceDirect
Contemporary Clinical Trials Communications
journal homepage: www.elsevier.com/locate/conctc
Searching for new biomarkers in ovarian cancer patients: Rationale and
design of a retrospective study under the Mermaid III project
Julie L. Hentzea, Claus Høgdallb, Susanne K. Kjærb,c, Jan Blaakærd,e, Estrid Høgdalla,∗
a Department of Pathology, Herlev Hospital, Herlev, Copenhagen University Hospital, Denmark
b Department of Gynecology, The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
c Unit of Virus, Lifestyle, and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
d Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark
e Department of Clinical Research, University of Southern Denmark, Odense, Denmark
A R T I C L E I N F O
Keywords:
Ovarian cancer
Diagnostic/prognostic biomarkers
MicroRNA
Epigenetics
Next Generation Sequencing
A B S T R A C T
Ovarian cancer is a silent killer and, due to late diagnosis, the primary cause of death amongst gynecological
cancers, killing approximately 376 women annually in Denmark. The discovery of a speciﬁc and sensitive
biomarker for ovarian cancer could improve early diagnosis, but also treatment, by predicting which patients
will beneﬁt from speciﬁc treatment strategies. The Mermaid III project is consisting of 3 parts including “Early
detection, screening and long-term survival,” “Biomarkers and/or prognostic markers” and “The infection
theory.” The present paper gives an overview of the part regarding biomarkers and/or prognostic markers, with
a focus on rationale and design.
The study described has 3 major branches: microRNAs, epigenetics and Next Generation Sequencing. Tissue
and blood from ovarian cancer patients, already enrolled in the prospective ongoing pelvic mass cohort, will be
examined. Relevant microRNAs and DNA methylation patterns will be investigated using array technology.
Patient exomes will be fully sequenced, and identiﬁed genetic variations will be validated with Next Generation
Sequencing. In all cases, data will be correlated with clinical information on the patient, in order to identify
possible biomarkers.
A thorough investigation of biomarkers in ovarian cancer, including large numbers of diﬀerent markers, has
never been done before. Besides from improving diagnosis and treatment, other outcomes could be markers for
screening, knowledge of the molecular aspects of cancer and the discovery of new drugs. Moreover, biomarkers
are a prerequisite for the development of precision medicine. This study will attack the ovarian cancer problem
from several angles, thereby increasing the chance of successfully contributing to saving lives.
1. Introduction
Ovarian cancer (OC) is the 5th most common cause of cancer death
for women, with a 5 year survival rate of only 52% in Denmark [1,2]. In
90% of OC cases the tumor is of epithelial origin, of which there are 5
histological subtypes; serous, endometrioid, clear cell, mucinous and
undiﬀerentiated. Serous carcinoma is counting nearly 70% of epithelial
OC tumors [3,4].
A primary cause for the high death rate of OC is that early OC
symptoms are unspeciﬁc and more than 60% of the patients are diag-
nosed at a late stage of disease (stage III/IV, International Federation of
Gynecology and Obstetrics, FIGO) [1,2,5,6]. At late stages the 5 year
survival is 15–29% whereas 88% of women diagnosed at stage I survive
more than 5 years [2]. If OC is suspected in a Danish patient, ex-
amination includes measurements of Cancer Antigen 125 (CA125)
serum levels and ultrasound scanning (Fig. 1). Risk of Malignancy Index
(RMI) is calculated based on these tests and the menopausal state of the
patient [4,7]. However, the speciﬁcity and sensitivity of CA125 as a
cancer marker is unsatisfactory [8–11]. A biological marker with high
sensitivity and speciﬁcity, which can detect early stages of OC, could
therefore improve survival. Biomarkers which have potential to be used
in screening programs are of highest priority. A screening strategy
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partly depending on CA125 was recently investigated, but with un-
satisfying results [11].
The best prognosis is obtained after radical surgery but un-
fortunately this is not always possible [4,12]. Standard treatment is
surgery followed by platinum-based chemotherapy combined with
taxane drugs, except for patients with stage IA-IB low grade and IA-IB
clear cell OC [4]. If complete resection is not possible, neoadjuvant
chemotherapy before interval surgery is an alternative [13], but tar-
geting patients for the relevant treatment is diﬃcult [14]. Moreover,
the majority of the patients respond to platinum-based treatment in-
itially, but 80% develop resistance and experience disease relapse [15].
A new promising ﬁeld in cancer-research is personalized precision
medicine, where the molecular proﬁle of a patients tumor is taken into
account during treatment [16]. However, predicting how the patients
will respond to medication is challenging. Biomarkers that support
speciﬁc treatment strategies could improve treatment. The search for
new biomarkers will also improve knowledge of the molecular me-
chanisms and help to identify new drug targets.
Mermaid is an organization with focus on gynecological cancers.
Earlier Mermaid projects have been very successful resulting in more
than 70 publications [17]. Resent technical improvements in molecular
biology have made it possible to investigate several molecular markers
simultaneously in large patient cohorts. The aim of the study described
here is to identify and validate new diagnostic, predictive and prog-
nostic biomarkers for OC, by using the underlying molecular char-
acteristics of the disease. The goal is to increase survival of OC patients
by improving diagnosis, ease treatment planning and by discovery of
new drug targets and possible screening markers.
2. Methods and design
2.1. Patients
All patient material used in the study will be from women enrolled
in “The pelvic mass study”, a prospective, ongoing cohort study in-
itiated in September 2004. Patients are included if they are 18 years or
older and admitted to surgery of a potentially malignant pelvic mass at
the Gynecologic clinic at Copenhagen University Hospital,
Rigshospitalet (Fig. 1). Patients are examined according to the Danish
Cancer Fast Track Guidelines and admitted to radical surgery or biopsy
for diagnosis followed by neoadjuvant chemotherapy [18]. Patients are
excluded from the pelvic mass study if they are unable to give informed
consent, are pregnant, have known relapse of previous cancer or have
another active cancer. All patient tissue is examined by specialized
pathologists and the patients are registered in the Danish Gynecologic
Cancer Database (DGCD, http://www.dgcg.dk/), where information
about clinical data, treatment and survival of the patient is updated
regularly.
2.2. Blood and tissue
Blood is sampled within 2 weeks prior to surgery and fractionated
into serum, buﬀy coat, EDTA plasma and whole blood within 6 h after
collection. Representative tissues are sampled and veriﬁed by the pa-
thologist. All blood and tissue samples (fresh frozen, RNA-later treated,
formalin ﬁxed and paraﬃn embedded tissues (FFPE) and O.C.T. com-
pounds) are registered and stored in Danish Cancer Biobank (www.
cancerbiobank.dk), and handled according to their guidelines. FFPE
tissue is kept at room temperature whereas all other tissue and blood
samples are stored at - 80 °C.
Fig. 1. Treatment of OC patients in Denmark, and inclusion in the Pelvic mass cohort. If a pelvic mass is suspected, the patient is examined by a gynecologist, whom will calculate
RMI based on ultrasound, CA125 and menopause status. Based on RMI the patient is either sent to general gynecological surgery, or a tertiary gyn-onc cancer center. PET_CT/MR
scanning determines the patient for either radical surgery with adjuvant chemotherapy or neoadjuvant chemotherapy with interval surgery. Women with a pelvic mass are enrolled in the
pelvic mass cohort when they are forwarded to surgery. OC: ovarian cancer, CA125: cancer antigen 125, US: ultrasound scanning, MP: menopausal state, RMI: Risk of malignancy Index,
gyn: gynecological, gyn-onc: gynecologic-oncology, PET_CT: Positron emission tomography–computed tomography, MR: Magnetic Resonance scanning.
J.L. Hentze et al. Contemporary Clinical Trials Communications 8 (2017) 167–174
168
2.3. Ethics
The Danish Ethical Committee approved the protocol according to
the rules used in International Conference on Harmonization/Good
Clinical Practice (ICH/GCP) recommendations and the Helsinki and
Tokyo conventions (KF01-227/03 and KF01-143/04, H-3-2010-022).
2.4. Sub-studies
2.4.1. MicroRNA
The small, single stranded, non-coding microRNAs (miRNAs) have
gone from being largely unknown to becoming widely recognized as
major players in gene regulation in less than 25 years. miRNAs bind to
partially complimentary mRNA sequences an inhibit translation,
thereby silencing gene expression in plants and animals [19]. miRNAs
are involved in the regulation of several important cellular processes,
including proliferation, diﬀerentiation, apoptosis and DNA repair, and
deregulated miRNAs are often found in cancer tissue [20,21]. Like
genes, miRNAs can be oncogenic, contributing to cancer progression by
being wrongly upregulated, or tumor suppressors, if cancer progression
is caused by lowered expression of the miRNA [22]. Typically, an on-
cogenic miRNA will inhibit expression of tumor suppressor genes, for
instance miRNA-21, which promotes proliferation, invasion and mi-
gration in OC by inhibiting expression of the tumor suppressor PTEN
[23]. On the other hand, the let-7 family of miRNAs is considered to be
tumor suppressors, and one of their actions is to suppress the oncogene
KRAS [24]. Several miRNAs has been shown to be deregulated in OC,
and miRNA expression proﬁles correlates with pathological conditions
including disease development, survival and drug-response [25–27].
miRNAs therefore hold a promising potential as both diagnostic and
predictive markers.
In order to identify new predictive miRNA markers, a correlation
between miRNA expression and chemotherapy resistance was
investigated in a retrospective study. The results of this study part have
been published elsewhere [28]. A total of 198 patients were included
(Fig. 2). All patients included had tumors of epithelial histology and
had completed primary surgery followed by treatment with a minimum
of two cycles of adjuvant chemotherapy with Carboplatin and Paclitaxel
or Docetaxel.
The correlation between miRNA expression and resistance to drug
treatment was predicted by the Medical Prognosis Institute (MPI) as
described previously [29,30] Growth inhibition (GI50) for a panel of
human cancer cell lines, the NCI60 cell line panel, when treated with
Carboplatin, Paclitaxel or Docetaxel, were compared to miRNA ex-
pression levels for each combination of miRNA and drug.
Total RNA was extracted from patient FFPE tissues using the
RecoverAll™ total nucleic acid isolation kit from Ambion at the
Molecular Unit at Herlev hospital. miRNAs was labeled using
FlashTag™ HSRTM Biotin RNA Labeling Kit from Genisphere and the
expression of 847 miRNAs was measured using an Aﬀymetrix®
GeneChip miRNA 1.0 array.
20 identiﬁed miRNA prediction markers, who showed the best
correlation with drug sensitivity, were then used to develop prediction
scores for each OC patient. The prediction scores were blindly vali-
dated, by comparing the clinical data on drug treatment and resistance,
overall survival (OS) and progression free survival (PFS) to the mea-
sured expression of the predictive miRNAs. Drug resistance was deﬁned
as relapse or progressive disease less than 6 months after treatment.
The miRNA expression data will also be compared to patient data
regarding tumor type, disease stage and grade, in order to investigate if
miRNA markers holds potential as diagnostic or prognostic markers.
Since patient blood samples are stored at −80 °C in the biobank, fur-
ther studies of miRNA expression in blood are possible to support data,
and regarding the use of circulating miRNAs to diﬀerentiate between
benign tumors and malignancy.
The labeled patient RNA will be used in similar investigations using
Fig. 2. Flow chart/study overview. Flow chart of the study “Biomarkers and/or prognostic markers”. All patient material used is collected from the Pelvic mass cohort. The study
contains 3 branches; a miRNA sub-study, an epigenetic sub-study and a NGS sub-study. Each sub-study aims at discovering and validating new biomarkers. OC: ovarian cancer, NGS: Next
Generation Sequencing, Exome-seq: Exome sequencing.
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mRNA arrays, to look at the correlation between gene expression and
clinical data like pathology, drug treatment and survival.
Identifying miRNAs, whose regulation can predict resistance to
chemotherapy, would greatly improve the treatment of OC patients.
Not only would the patients avoid a toxic treatment with more side-
eﬀects than eﬀects, the predictions made could also ease and speed up
the unset of alternative more personalized treatment, increasing the
chance of survival.
miRNAs may hold a great potential as diagnostic markers, and cir-
culating miRNAs are stable in body ﬂuids and can therefore be detected
in blood-tests [31]. It has been shown that cancer-speciﬁc miRNAs
circulating in tumor exosomes can be detected already in early stages of
OC, and the level of exosome miRNAs might hold the potential to dif-
ferentiate between benign disease and stage I cancer [32,33].
miRNAs has also gained focus as possible therapeutic agents.
Because miRNAs recognize their targets by partial complementarity,
one miRNA often regulate several diﬀerent genes. Even though the
complexity of this system can be challenging, it also has a huge ad-
vantage, since drugs that mimic one miRNA might be capable of si-
lencing several oncogenes at the same time, thereby attacking the
cancer through several diﬀerent pathways. This tactic has led to the
ﬁrst phase 1 trial of a drug that mimics a miRNA, namely miR-34a,
which targets more than 30 oncogenes and is often downregulated in
cancer [34].
2.4.2. Epigenetics
The new knowledge, that gene-regulation can be altered in an in-
heritable way, carried in the chromosome but without changing the
DNA sequence, opens for new possibilities when it comes to cancer-
treatment. It is easier to change epigenetic regulation of genes than it is
to repair mutated or damaged DNA in the patient [35]. One of the most
well studied epigenetic mechanisms has also been related to cancer.
DNA methylation, where methyl groups are added to the nucleotide
cytosine, is a process that can alter gene expression in a stable manner
[36]. High levels of methylation in a promoter region inhibit gene
transcription. The process of DNA methylation is essential in embryonal
development, where it is involved in silencing of genes important for
cell diﬀerentiation in embryonic stem-cells and in X-chromosome in-
activation. However, erroneous changes in DNA methylation-patterns
are often seen in carcinogenesis [37]. Increasing levels of DNA me-
thyltransferase and localized hypermethylation has been observed,
especially in the promotors of tumor suppressors [38,39]. However,
reduced methylation of oncogene promoters or genome wide hypo-
methylation, resulting in chromosome instability, has also been ob-
served in cancer [40,41]. In some OC patients, the PolyComb Group
Target genes (PCGTs), essential for diﬀerentiation, are hypermethy-
lated [42,43]. Another group of genes, MESC, which are named this as
they are normally highly Methylated in Embryonic Stem Cells, become
hypomethylated in OC. While the PCGT hypermethylation can be de-
tected very early, before unset of carcinogenesis, the hypomethylation
of MESC progresses from primary cancer to metastasis [43]. In this way,
the status of speciﬁc methylation sites of cancer cell DNA can both be
used to diagnose early stages of cancer and work as prognostic in-
dicators.
Patterns of DNA methylation which can be used either diag-
nostically, in screening, or as prognostic or predictive markers, will be
investigated in a retrospective study. 60 OC patients and 30 age-mat-
ched controls will be included (Fig. 2). Patients from whom we have
both blood samples, cytological cervix samples from smear testing and
both fresh frozen- and FFPE tissue will be prioritized. The cancer
samples will include both early and late stage epithelial cancers and
both blood and tissue will be analyzed. Corresponding cervical smear
samples will also be included for 40 patients, diagnosed with early and
late OC stages. The reason for including cervical smear samples will be
explained later. Both platinum-resistant and platinum-responsive pa-
tients will be assessed. The non-cancerous controls included as
references will both include benign or borderline tumors as well as
normal tissue from healthy women.
For discovery of global methylation proﬁles and relevant methyla-
tion sides, patient DNA will be puriﬁed from blood, fresh frozen tissues
or FFPE, using the Maxwell® rsc DNA puriﬁcation systems from
Promega, at the Molecular Unit, Department of Pathology at Herlev
University Hospital. As DNA from FFPE samples may be partly de-
graded, these samples will be restored with the Inﬁnium® HD FFPE
restore kit. To begin with, fresh frozen and FFPE samples will be run in
parallel in order to ensure concordance between results using DNA from
FFPE samples and DNA from frozen material. The DNA will be bisulﬁte
treated with the EZ DNA Methylation™ kit (Zymo Research). Bisulﬁte
converts non-methylated cytosine to uracil, thereby changing the ge-
netic code in non-methylated areas. Global methylation proﬁles will be
identiﬁed using the Inﬁnium® MethylationEPIC BeadChip Kit (Illumina)
in the lab of Associate Professor Jesper B. Andersen at the Biotech
Research and Innovation Center, University of Copenhagen. The group
already has the Inﬁnium® Methylation EPIC array technology im-
plemented in the lab, studying other cancer types, and the OC samples
will be run under his supervision. The methylation array distinguishes
between methylated DNA or the bisulﬁte converted non-methylated
DNA by hybridization to DNA-probes speciﬁc for either the methylated
or non-methylated allele. The methylation pattern of 850.000 cancer
related targets, including promotors and enhancers of tumor suppressor
genes, will be investigated.
Changes in gene expression of aﬀected genes will be validated by
qPCR for a maximum of 5–10 methylation sites discovered by the array.
Patient RNA will be puriﬁed from both fresh frozen tissue and from
FFPE tissue from 200 OC tumors and 100 benign tumors.
The obtained methylation data will be blindly correlated with
clinical data for the involved patients. The focus will be both on data
regarding drug resistance, to identify predictive and prognostic mar-
kers, on data regarding malignancy and cancer stage, to identify diag-
nostic markers and ﬁnally on the correlations between methylation
patterns in diﬀerent sample types of early stage cancers, to identify
screening markers.
Changes in methylation patterns can occur very early in cancer
development, and therefore holds potential for screening and diﬀer-
entiating between benign conditions and cancers [43,44]. Another
important parameter that underscores the diagnostic potential of me-
thylation patterns is that tumor-speciﬁc, methylated DNA is accessible
pre-surgical. It has been shown that it can be obtained from serum or
plasma as circulating DNA, and that the cell free, tumor-speciﬁc, me-
thylated DNA is highly biologically stable, and therefore holds a bio-
marker potential [45,46]. High grade ovarian carcinomas, which con-
stitute the largest and most aggressive group of OC tumors, have been
shown to originate primarily from the fallopian tube rather than from
ovarian tissue [47,48]. Fluid and oocytes pass from the tubes and
through cervix and the tubes and cervix are parts of the same organ. It
can therefore be speculated that stable biomarkers from the ovaries,
like methylated DNA, which indicate changes in pre-malignant or ma-
lignant tissue of tubal origin, can be detected in the cervical canal [49].
If a highly speciﬁc and sensitive methylation-based marker for OC was
identiﬁed, it is hypothetically possible that it could be detected in a
cervical smear test, and that screening for ovarian cancer could be in-
cluded in the already implemented smear-testing and screening for
cervix cancer.
Reversing false DNA methylation also holds potential for treatment.
Drugs inhibiting the enzyme DNA methyltransferases has been ex-
tensively studied for this purpose, and several preclinical studies have
shown that their hypomethylating eﬀect can reactivate transcription
and probably re-sensitize patients to treatment [50].
Promising results from this sub-study will possibly be followed up
by a larger, national, prospective multicenter study, and if possible an
international study as well.
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2.4.3. Next Generation Sequencing (NGS)
Cancer can arise because of deregulation of genes important for
growth, development or other crucial processes, but often the cause of
cancer is mutation, deletion or even duplication of the gene itself [51].
The mutation may interfere with the function of a gene involved in
tumor suppression or turn a proto-oncogene into an oncogene by in-
creasing its activity. Several cancer-related mutations are already
known and used as biomarkers for other cancers. Mutations in the gene
encoding the tumor suppressor p53 or in one of the RAS proto-onco-
genes, HRAS, KRAS and NRAS, are amongst the most abundant muta-
tions found in cancer and also amongst the most studied genes [52,53].
The gene coding for p53 is mutated in approximately 45% of OCs
[54], and previous data from the Danish MALOVA study (MALignant
OVArian cancer study) has indicated that p53 may function as a
prognostic marker in OC patients, as a signiﬁcantly shorter survival was
observed for patients with missense mutations in the gene encoding p53
[55]. On the other hand, mutations in KRAS are found in a smaller
percentage of OCs and primarily in low-grade serous carcinomas and
mucinous carcinomas [56].
Another set of mutations which are relevant for OC is the BRCA
mutations found in approximately 10% of OCs. BRCA genes have an
important function in DNA-repair and can be inherited from the parents
and they are a major risk factor for developing OC with a lifetime risk of
40–60% [57,58].
Sequencing technology and related DNA tools are constantly evol-
ving and the development of Next Generation Sequencing (NGS) has
opened for a wide array of new possibilities when it comes to in-
vestigating mutations in cancer patient cohorts [59]. Sequencing of
several hundreds of genes simultaneously in large patient cohorts will
facilitate the discovery of new cancer-related mutations and the in-
vestigation of the correlation between mutations and clinical data, like
patient survival. Moreover, the data that can be generated with NGS
can help us to a better understanding of the etiologies of OC, and to a
more thorough investigation of the involvement of the known cancer-
related genes, like TP53 and KRAS, in OC.
This study part will be initiated with a genome-wide discovery
phase. In order to identify mutations that can be used as prognostic
markers for ovarian-cancer, all protein-coding DNA sequences in the
genome will be investigated by exome-sequencing for selected patients.
DNA from 50 OC patients will be suﬃcient to obtain a satisfying sta-
tistical power and reliable results for this part of the study (Fig. 2).
Patients with diﬀerent clinical outcomes will be included. The patient
samples will cover epithelial tumors of diﬀerent stages, histological
subtypes and grades, and each group should be represented by at least 5
patients.
Maxwell® rsc DNA puriﬁcation systems from Promega will be used
to purify patient DNA from fresh frozen or FFPE tissue. Exome en-
richment of patient DNA is done by multiplex PCR Sequencing of the
Exome library will be done on a chip (Ion 540 chip kit) with the Ion
540™ Kit-OT2 (Thermo Fisher Scientiﬁc).
Mutations discovered by the exome sequencing will be validated
with NGS using the Ion torrent Oncomine comprehensive panel, sup-
plemented with primers for additional targets identiﬁed in the exome
sequencing if necessary. Approximately 400 genes will be included
(hot-spots), comprising tp53, KRAS, HRAS, NRAS and the BRCA genes.
DNA from 100 patients will be included and sequenced. Datamining
will be performed using existing software.
Data on patient mutational state will be blindly compared with the
clinical data for the involved patients, including disease stage, grade,
chemotherapy resistance and survival (OS and PFS) and tumor type.
Mutations that holds potential as prognostic or predictive markers,
discovered and validated by exome sequencing and targeted/panel se-
quencing, will be used to design a primer panel specialized for OC
patients. The panel will be tested on DNA from 300 patients. The pa-
tient samples should represent a broad spectrum of epithelial OCs,
grouped by stage, histological subtype and grade, also including benign
ovarian tumors.
The assessment of predictive mutations in cancer related genes is
already an integral part of the clinical work. An example of this is that
KRAS mutational status is routinely examined and used for patients
with colorectal cancer [60,61]. KRAS mutations in a tumor predict a
poor response to certain kinds of targeted treatment [62]. This strategy
spares the relevant patients from numerous side eﬀects, and the hos-
pital for wasting expensive drugs on those who do not beneﬁt from it.
In OC treatment BRCA mutations are used to assess which OC pa-
tients will beneﬁt from treatment with poly(adenosine diphosphate
[ADP]-ribose) polymerase (PARP)-inhibitors [4,63]. Both PARP and the
BRCA proteins are involved in DNA repair, and PARP-inhibition can
therefore kill cancer cells with BRCA mutations. However, a great
breakthrough came recently in this area when Mirza et al. showed that
the PARP-inhibitor Niraparib can prolong PFS signiﬁcantly in all pla-
tinum-sensitive OC-patients, even though the eﬀect was most sig-
niﬁcant in patients with BRCA mutations [64].
Identiﬁcation of new similar predictive mutations in OC patients
could likewise improve the treatment of OC patients, but also improve
the understanding of the molecular mechanism in OC etiologies. New
knowledge in this area can lead to new drug targets. Moreover, new
predictive biomarkers are of the highest importance for the improve-
ment of cancer treatment, as more personalized and targeted treatment
calls for new possibilities to identify the patients who will beneﬁt from
a speciﬁc treatment.
3. Results
The study is expected to generate a vast amount of results and we
plan to publish 10–15 papers in relation to it. The ﬁrst promising re-
sults, regarding miRNAs and prediction of resistance to platinum-based
drugs, has already been published in the paper “Clinical validation of
chemotherapy predictors developed on global microRNA expression in
the NCI60 cell line panel tested in ovarian cancer” [28].
4. Discussion
Traditionally, cancer has been treated medically with chemotherapy
which interferes with the cell cycle [4]. It has been a “one size ﬁts all”-
approach were cancer is treated as a primarily homogenous disease.
However, not all patients respond equally well to chemotherapeutic
treatment, and the risk of developing resistance is high. A primary
reason for the diversity in reaction-pattern is, that cancer is a very
heterogeneous condition [51,65]. With the continuing improvement in
molecular areas like ”omics,” and the increasing knowledge of mole-
cular disease etiologies, cancer is now seen as a large array of individual
diseases rather than the limited number of cancers grouped by organ
and histology that we have operated with until now. This enables a
more personalized and eﬀective treatment, and even treatment targeted
directly at speciﬁc molecules. However, it is a prerequisite for this
development, that clinical data from patient cohorts will be collected
systematically, along with tissue and blood samples [16]. In this way,
small patient groups with similar disease proﬁles, or even individuals,
can be studied and followed retrospectively in order to identify markers
that characterize the cancer at an individual level and predict which
patients will beneﬁt from a particular specialized therapy. The thor-
ough collection of information is a great challenge as it takes a lot of
resources. However the Danish Cancer Biobank and DGCD are working
ahead of this problem, as we already are collecting and storing both
information and biological samples from all cancer patients who agree
to it. The thorough collection of patient data and material is unique to
Denmark and holds a great research potential.
One of the great beneﬁts of storing patient material and data is that
it makes translational research possible and eases the work of identi-
fying new biomarkers. New biomarkers are needed, as CA125 levels are
only increased in 50% of patients with stage I OC, and CA125 can be
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elevated in other cancers or benign conditions [8–10]. A lot of work is
already being done in this ﬁeld. In 2009 FDA approved the use of a
multivariate index assay called OVA1, which evaluate serum con-
centrations of 5 diﬀerent markers (CA125-II, transferrin, transthyretin,
apolipoprotein AI, and beta 2 microglobulin) [66,67]. The test has a
high sensitivity compared to CA125 alone, but a low speciﬁcity.
Another biomarker for OC which has gained a lot of interest recently
is the glycoprotein Human Epididymis Protein 4 (HE4). It is highly
expressed in the epithelial OC with no expression in healthy ovaries
[68]. It has been shown that HE4 might be a better diagnostic OC
marker than CA125, as it diﬀerentiates not only between benign and
malignant disease with a higher sensitivity for cancer, but also between
early FIGO stages of epithelial OC and benign conditions [69–72].
However, an even bigger eﬀect is seen if HE4 and CA125 are combined,
and this led Moore et al. to develop the Risk of Ovarian Malignancy
Algorithm (ROMA), which besides from Serum HE4 and CA125 levels
also includes menopausal status [70,73]. The majority of OC patients
are postmenopausal when diagnosed [74]. The authors own results
suggest that ROMA can improve diﬀerentiation between OC and benign
disease compared to RMI, but the results of other studies have been
diverging when it comes to the performance of the ROMA index
[69,72,75]. By combining serum levels of HE4 and CA125 with age
instead of menopausal stage, Karlsen et al. has developed the Co-
penhagen Index (CPH-I), and according to their results CPH-I, ROMA
and RMI perform equally well when it comes to diﬀerentiating between
benign conditions and OC [76,77]. This has been conﬁrmed by another
study [78]. CPH-I might have an advantage compared to the other two
indices, in that it only takes a blood test and knowledge of patient age,
which makes it highly reproducible and easy to apply in a clinical
setting.
Screening markers, which have high sensitivity and speciﬁcity and
which could be measured pre-surgery in a blood test or cervix smear,
has long been wished for. Recently, the UK Collaborative Trial of OC
Screening (UKCTOCS) was published [11]. More than 200.000 women
were included in this study, which is the largest randomized controlled
study to evaluate a strategy for screening of OC. Participants were
randomly screened using transvaginal ultrasound or the use of the Risk
of Ovarian Cancer Algorithm (ROCA). ROCA calculates a statistical risk
of OC from a series of CA125 serum level measurements, rather than the
use of a single cutoﬀ value [79]. This method omits some of the pro-
blems with the natural variation in CA125 levels, as focus is on the
changes in CA125 level compared with a woman's own baseline level.
However, the results of the large UKCTOCS screening were not as
promising as hoped for, as there was no signiﬁcant reduction in mor-
tality in the primary analysis [11]. A signiﬁcantly reduced mortality
rate was observed when prevalent cases were removed, indicating that
it may be possible to identify early stage OCs by the use of screening.
Yet, OC is still the leading cause of death from gynecological malig-
nancies and new markers and a better understanding of the disease
etiology are needed if we wish to see a signiﬁcant decline in deaths.
Large screenings for cancer-related molecular changes, as the ones in-
itiated under this study, holds the potential of bringing us closer to this
goal, especially because we are doing a combined eﬀort, not only in-
vestigating genetics, but also two diﬀerent mechanism of gene regula-
tion. Dysregulation of both DNA methylation and miRNAs have been
shown to be highly involved in carcinogenesis. We need to study several
types of biomarkers in order to identify sensitive and speciﬁc markers
for both diﬀerentiation between disease and benign conditions and
prediction of sensitivity to treatment, especially since there is a slight
variation in the challenges and advantages between diﬀerent kinds of
molecular markers. The more classical way of working with nucleotides
as biomarkers, is by assessing genetic changes like mutations. Cancer
genetics is a well-studied ﬁeld, and mutations have already proven
useful as predictive and prognostic markers. However, mutations are
not well suited in early diagnostics and screening, as ovarian cancer
tissue is only accessible under surgery. Even though tumor DNA from
dead cancer-cells can be found in circulation in the blood, it is not easily
detectable due to the large background of cell free DNA present in
circulation [80]. However, genetic changes are still important when it
comes to precision medicine. Exome sequencing has made it possible to
investigate the whole coding region of genomes, increasing the chance
of discovering new biomarkers and drug-targets. When developing new
drugs, it may also be easier to avoid side eﬀects if the target is a single
gene, and not regulatory units like miRNAs which may have many
targets that will be aﬀected simultaneously.
Both miRNAs and methylated DNA has great potential as prognostic
and diagnostic markers, as changes in miRNA expression and DNA
methylation has been correlated to diﬀerent pathogenic processes in-
cluding early carcinogenesis, metastasis and to sensitivity to treatment.
DNA methylation is particularly interesting for screening and early
diagnosis, as changes in methylation often precedes carcinogenesis and
since circulating, methylated tumor DNA is more stable than RNAs or
protein [81]. Moreover, methylation patterns are easier to detect than
mutations as they are binary signals and can be ampliﬁed by methy-
lation speciﬁc PCR-based techniques. Since DNA methylation is a re-
versible process, hypomethylating agents also has a promising potential
in treating cancer and chemo resistance caused by erroneous methy-
lation of promotors of tumor suppressors.
Despite the fact that body-ﬂuids contain nucleases that degrade
RNA, miRNAs in circulation are stable and protected, which makes
them very suitable as biomarkers [31]. miRNAs, or miRNA antagonists,
also has a huge therapeutic potential, as one miRNA often regulates
several oncogenes or tumor suppressor genes, aﬀecting more than one
pathway.
The latest research in the area of OC has indicated that screening
and early prognosis may be possible in the future and that resistance to
treatment can be overcome by precision medicine. We might already be
moving towards making OC a chronic disease which the patient can live
with if well-treated. However, the goal is to make it a cancer which, in
most cases, is discovered and treated before it spreads and becomes
untreatable, even with the use of therapy, thereby improving survival.
Mermaid III will reveal new and extensive information which can
possibly be used to extend or save the lives of OC patients.
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